Literature DB >> 12648870

Pre-pubic TVT: an alternative to classic TVT in selected patients with urinary stress incontinence.

N Daher1, J C Boulanger, U Ulmsten.   

Abstract

OBJECTIVES: To evaluate in a prospective open study a pre-pubic route of TVT for surgical treatment of female stress incontinence. STUDY
DESIGN: Consecutively, 74 patients were operated using a pre-pubic TVT tape application. All women were suffering subjectively and objectively from female stress urinary incontinence. The mean post-operative follow-up time was 5 months (range 2-10 months). The pre- and post-operative evaluations were performed according to a standard protocol.
RESULTS: According to the protocol, 60 patients (81%) were cured of their stress incontinence symptoms. Another 10 patients (13%) were improved. Four patients (6%) were considered failures. There were no significant intra- or post-operative complications.
CONCLUSION: The short-term results of pre-pubic TVT are consonant with those of classic TVT. The risks of intra-operative complications should be reduced by the pre-pubic route. If the long-term results of pre-pubic TVT are the same as those after classic TVT, then this surgical approach may be a tentative alternative in selected high-risk patients. Copyright 2003 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 12648870     DOI: 10.1016/s0301-2115(03)00051-4

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Analysis of risk factors associated with surgical failure of inside-out transobturator vaginal tape for treating urodynamic stress incontinence.

Authors:  Huey-Yi Chen; Lian-Shung Yeh; Wei-Chun Chang; Ming Ho
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-08-15

Review 2.  Urethral slings placed by the transobturator approach: evolution in the technique and review of the literature.

Authors:  Alan W Shindel; Carl G Klutke
Journal:  Curr Urol Rep       Date:  2005-09       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.